Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.

Payne, Christopher D; Li, Ying Grace; Small, David S; Ernest, C Steven; Farid, Nagy A; Jakubowski, Joseph A; Brandt, John T; Salazar, Daniel E; Winters, Kenneth J

Payne, Christopher D; Li, Ying Grace; Small, David S; Ernest, C Steven; Farid, Nagy A; Jakubowski, Joseph A; Brandt, John T; Salazar, Daniel E; Winters, Kenneth J.

Affiliation

Payne CD; Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK.

J Cardiovasc Pharmacol ; 50(5): 555-62, 2007 Nov.

Article in En | MEDLINE | ID: mdl-18030066

Subject(s)

Piperazines/pharmacokinetics; Platelet Aggregation Inhibitors/pharmacokinetics; Platelet Aggregation/drug effects; Thiophenes/pharmacokinetics; Ticlopidine/analogs & derivatives; Adenosine Diphosphate/pharmacology; Adult; Area Under Curve; Blood Platelets/cytology; Blood Platelets/drug effects; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines/metabolism; Piperazines/pharmacology; Platelet Aggregation Inhibitors/metabolism; Platelet Aggregation Inhibitors/pharmacology; Prasugrel Hydrochloride; Thiophenes/metabolism; Thiophenes/pharmacology; Ticlopidine/metabolism; Ticlopidine/pharmacokinetics; Ticlopidine/pharmacology

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Piperazines / Thiophenes / Ticlopidine / Platelet Aggregation Inhibitors / Platelet Aggregation Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 2007 Type: Article

Search on Google

XML

PubMed Links